MENU
IMVT
Stock ticker:
PRICE
CHANGE
CAPITALIZATION
Immunovant (IMVT) Ownership - Who owns Immunovant?
Profile
Industry
N/A
Address
320 West 37th Street
Phone
+1 917 580-3099
Employees
164
Web
https://www.immunovant.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
4.1B
P/E Ratio
N/A
Total Cash
560.01M
Projected Growth
N/A
Total Debt
69K
Revenue
N/A
Risk (Beta)
0.69
Dividend Yield
N/A
Total Cash/Share
3.83
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
IMVT
Capitalization
4.1B
P/E Ratio
N/A
Risk (Beta)
0.69
Dividend Yield
N/A
Total Cash
560M
Total Cash/Share
3.83
Total Debt
69K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
545M
P/B Ratio
7.66
Cash Flow
N/A
Earnings
-1.91
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
14K
Current Ratio
13.08
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-298.26M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-57.93
Shares Held By Institutions
3.45B
Shares Outstanding - Current
146M
Total Liabilities
45M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-30.762
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
320 West 37th Street
Phone
+1 917 580-3099
Employees
164
Web
https://www.immunovant.com